Budesonide/formoterol

Drug Profile

Budesonide/formoterol

Alternative Names: Alenia; Formoterol/budesonide; Symbicort; Symbicort pMDI; Symbicort SMART; Symbicort Turbuhaler

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biosintetica
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Nov 2016 AstraZeneca submits results of the phase III CHASE trial in Asthma to the US FDA and other health authorities
  • 11 Nov 2016 Efficacy data from the phase III CHASE trial in Asthma (In children) presented at the 2016 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2016)
  • 01 Nov 2016 AstraZeneca initiates a phase I bioavailability trial in Healthy volunteers in United Kingdom (Inhalation) (NCT02934607)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top